Siemens Healthineers: Not yet done ☝️Siemens Healthineers took a step south at the beginning of the year, but has since almost made up for this setback on the upside. Nevertheless, we have drawn up a new alternative scenario with a 30% probability on the chart, according to which the current rise would already be completed with the last high in the form of the magenta-colored wave alt.(X). Accordingly, the price would fall below the support level of €45.51 earlier and consequently into our turquoise-colored Target Zone between €40.32 and €36.13. As part of our primary scenario, however, we give the stock a little more room on the upside - namely until just above the resistance at €53.98 - in order to underpin the top of the regular magenta-colored wave (x). Only then should it dive into the turquoise Target Zone.
SHL
SHL - Bearish Trend ConfirmationSHL - Bearish Trend Confirmation Indications:
1. The trend has got weak on the Weekly and Monthly with Bearish Engulfing Candles
2. The price has broken the trendline which is confirmation of a bearish trend
3. The down move was a powerful and impulsive wave
I expect price to retrace on the upside, and I expect price to get weak at or near (Resistance 1 ~ $34.85 level) or (Resistance 2 ~ $36.75 level), where sellers may attempt to dump the stock and form a Lower High. I expect price to get dumped from either of the Resistance Levels. I believe that buying now is Risky. The ideal level and extremely Strong Support Zone is between ~ $26.50 - ~ $27.30, but it is not necessary that price may drop all the way down to these levels. There may be little swings on the way down but will have to see where SHL finds strong support. I would be a confident buyer at that strong support level for a long term position.
Please note these are my own notes, by no means trading advice. Please do your own research before entering into any trade.
SHL Siemens potential path into Germany’s benchmark DAX30 indexThe $16.4 billion purchase of Varian Medical Systems not only gives Siemens Healthineers AG an entry into cancer treatment -- one of the hottest areas in medical technology -- but also opens a potential path into Germany’s benchmark DAX index.
“We’ll create additional free float which eventually will lift us into the DAX,” Chief Executive Officer Bernd Montag said in an interview with Bloomberg TV. “We are very certain about this transaction, it’s the right time, and we are super confident about financing.”
The Erlangen, Germany-based maker of MRI machines and laboratory equipment announced Sunday it’s offering $177.50 a share for Palo Alto, California-based Varian, 24% more than its closing price on Friday. Bloomberg was first to report the offer on Saturday.
With Varian, Healthineers will gain market share in devices and software used for cancer therapy. Recent developments in radiation therapy, coupled with more precise imaging, have been linked to lower cancer death rates, which Montag said the company is keen to capitalize on.
The deal has “clear strategic rationale,” Citigroup analyst Kate Kalashnikova said in a note. “The combined company will have the most comprehensive cancer portfolio in the industry.”
The deal is the biggest health-care acquisition this year.
Source: Bloomberg
If you are interested to test some amazing buy and sell indicators, which give the signal at the beginning of the candle, not at the end of it, just leave me a message.
Siemens Healthineers buys US cancer therapy company Varian $16BGermany-based Siemens Healthineers said Sunday it will buy U.S. cancer therapy and research company Varian in a deal worth around $16.4 billion.
Siemens Healthineers SHL, -5.32%, in which industrial conglomerate Siemens holds a majority stake, said it will buy all shares in Varian Medical Systems, Inc. VAR, +3.18% for $177.50 per share in cash.
It said that the acquisition is expected to close in the first half of 2021, and requires the approval of regulators and Varian shareholders. Varian’s board of directors unanimously approved the agreement, it added.
Palo Alto, California-based Varian had revenues in the 2019 fiscal year of $3.2 billion, Siemens Healthineers said in a statement. Varian says it employs about 10,000 people around the world.
Siemens Healthineers said it plans to finance the acquisition with a mix of debt and equity.
Source: MarketWatch
If you are interested to test some amazing buy and sell indicators, which give the signal at the beginning of the candle, not at the end of it, just leave me a message.
$SHL $SHL.ASX - Double Top , Short term target $26.03SONIC HEALTHCARE LIMITED
Double Top , Short term target $26.03
Sonic Healthcare is one of the world's largest medical diagnostics companies, providing laboratory and radiology services to medical practitioners, hospitals, community health services, and their collective patients.
P/E 22.640
EPS 1.240 AUD
Annual dividend yield Help 3.03
Directors/Senior management
Mr Mark R Compton Non Exec. Chairman
Dr Colin S Goldschmidt Managing Director, CEO, Executive Director
Mr Philip Dubois Executive Director
Mr Christopher Wilks Executive Director, Finance Director
Mr Neville Mitchell Non Exec. Director
Prof. Suzanne Crowe Independent Director
Mr Lou Panaccio Independent Director
Ms Kate D Spargo Independent Director
Dr Jane Wilson Independent Director